Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 0.48 |
| ▸ | MMP9 | P14780 | 20/20 | 0.48 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860511 | 0.86 | MMP2 (0.47) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6291932 | 0.85 | MMP2 (0.48) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4654577 | 0.84 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6296089 | 0.84 | GSK3B (0.55) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7378575 | 0.84 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7347186 | 0.84 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7865124 | 0.84 | TSHR (0.58) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8482551 | 0.84 | MMP2 (0.52) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7864883 | 0.82 | MMP2 (0.45) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4318837 | 0.82 | MMP2 (0.56) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5968795-A | ANTIARTHRITIC/ANTIINFLAMMATORY/ANTIMETASTASIS/ANTIFERTILITY/ ANTITUMOR AGENTS; FOR TREATMENT OF ORAL/CARDIOVASCULAR DISEASES, VISION DEFECTS, PROTEINURIA, DYSTROPHOBIC EPIDERMOLYSIS, BULLOSA, BONE/NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |